2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 12th, 2025
Version: 3
Duke University
cancer biology
biorxiv

IL-7-mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models

Singh, K.Open in Google Scholar•Hotchkiss, K. M.Open in Google Scholar•Cook, S. L.Open in Google Scholar•Noldner, P.Open in Google Scholar•Zhou, Y.Open in Google Scholar•Moelker, E. M.Open in Google Scholar•Railton, C. O.Open in Google Scholar•Blandford, E. E.Open in Google Scholar•Puviindran, B. J.Open in Google Scholar•Wallace, S. E.Open in Google Scholaret al.

The efficacy of T cell-activating therapies against glioma is limited by an immunosuppressive tumor microenvironment and tumor-induced T cell sequestration. We investigated whether peripherally infused non-antigen specific autologous lymphocytes (ALT) could accumulate in intracranial tumors. We observed that non-specific autologous CD8+ ALT cells can indeed accumulate in this context, despite endogenous T cell sequestration in bone marrow. Rates of intratumoral accumulation were markedly increased when expanding lymphocytes with IL-7 compared to IL-2. Pre-treatment with IL-7 ALT also enhanced the efficacy of multiple tumor-specific and non-tumor-specific T cell-dependent immunotherapies against orthotopic murine and human xenograft gliomas. Mechanistically, we detected increased VLA-4 on mouse and human CD8+ T cells following IL-7 expansion, with increased transcription of genes associated with migratory integrin expression (CD9). We also observed that IL-7 increases S1PR1 transcription in human CD8+ T cells, which we have shown to be protective against tumor-induced T cell sequestration. These observations demonstrate that expansion with IL-7 enhances the capacity of ALT to accumulate within intracranial tumors, and that pre-treatment with IL-7 ALT can boost the efficacy of subsequent T cell-activating therapies against glioma. Our findings will inform the development of future clinical trials where ALT pre-treatment can be combined with T cell-activating therapies.

Similar Papers

biorxiv
Sun Apr 13 2025
PI5P4Kα Regulates Iron Balance to Promote Metabolic Fitness in Pancreatic Cancer
Phosphoinositide kinases generate distinct phosphoinositides that regulate processes that maintain cellular fitness. Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) have garnered interest for their role in cancer metabolism and cellular trafficking; however, their function in pancreatic ductal adenocarcinoma (PDAC) remains unexplored. Given the unique metabolic demands of PDAC cells, which he...
Arora, G. K.
•
Loughran, R. M.
•
Ly, K.
•
Galapate, C. M.
...•
Emerling, B. M.
biorxiv
Sun Apr 13 2025
Exosomal cargo genes as biomarkers and potential mediators of exosome-driven cell communication in Pleural Mesothelioma
Pleural mesothelioma (PM) is a rare yet aggressive and heterogeneous cancer type with very poor survival rates. Due to its long latency period and nonspecific symptoms, the disease is usually detected at advanced stages, limiting available treatment options and leading to poor survival rates. So far, the disease can only be confirmed through invasive thoracoscopic biopsy, and proposed circulating ...
Kraft, A.
•
Toenz, A.
•
Schlaepfer, F.
•
Ronner, M.
...•
Meerang, M.
biorxiv
Sun Apr 13 2025
Novel Strategy against AML by Rescuing Loss of Phase Separation of Pathogenic NPM1c
Nucleophosmin (NPM1) is a nucleolar protein that participates in many biological processes through phase separation. In acute myeloid leukemia (AML), nearly one-third of cases harbor NPM1c mutations. Previous studies mainly focused on the contribution of the additional NES in NPM1c mislocalization and AML development; however, the mechanisms underlying the relationship between aberrant localizatio...
Li, P.
•
Zhu, Y.
•
Xu, W.
•
Wang, R.
...•
Zhu, H.
biorxiv
Sun Apr 13 2025
Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma
The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by a limited infiltration of tumor-specific T cells and anti-tumor T cell activity. Extracellular factors in the PDAC TME have been widely reported to mediate immune suppression, but the contribution from tumor-intrinsic factors is not well understood. The RNA-binding protein, HuR (ELAVL1), is enriched in ...
Guo, Y.
•
Finan, J. M.
•
Bartlett, A. Q.
•
Sivagnanam, S.
...•
Eil, R.
biorxiv
Sat Apr 12 2025
Dual Targeting for Enhanced Tumor Immunity: Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation
Reinvigoration of tumor-reactive T-cells using co-stimulatory bispecific antibodies (bsAbs) targeting CD28 or CD137 is emerging as a promising therapeutic strategy. Conditional, tumor-specific recruitment can offer a necessary layer of control and specificity. We developed pH-selective CD28xVISTA bsAbs to act specifically within the acidic tumor microenvironment (TME), aiming for enhanced T-cell-m...
Thisted, T.
•
Smith, F. D.
•
Jiang, Z.-G.
•
Onumajuru, A.
...•
van der Horst, E. H.
biorxiv
Sat Apr 12 2025
The differential effect of glutamine supplementation on the orthotopic and subcutaneous growth of two syngeneic murine models of glioma
Glutamine serves as a major fuel source for tumor cell proliferation while simultaneously playing an essential role in maintaining gastrointestinal health and immune function. Controversy exists regarding glutamine supplementation for cancer patients undergoing chemotherapy and radiation, with concerns that it may stimulate cancer growth. The present study is the first to examine the effects of di...
Maurer, J.
•
Mukherjee, P.
•
Ta, N.
•
Lee, D. C.
...•
Seyfried, T. N.
biorxiv
Sat Apr 12 2025
Resilience and vulnerabilities of tumor cells under purine shortage stress
Purine metabolism is a promising therapeutic target in cancer; however how cancer cells respond to purine shortage,particularly their adaptation and vulnerabilities, remains unclear. Using the recently developed purine shortage-inducing prodrug DRP-104 and genetic approaches, we investigated these responses in prostate, lung and glioma cancer models. We demonstrate that when de novo purine biosynt...
Yu, J.
•
Jin, C.
•
Su, C.
•
Moon, D.
...•
Huang, J.
biorxiv
Sat Apr 12 2025
Identification of Injury-Response State Determinants in Glioblastoma Stem Cells
Glioblastoma (GBM) is a common and highly lethal type of primary brain tumor in adults. Therapeutic failure is partly attributed to a fraction of Glioblastoma Stem Cells (GSCs) that show high levels of heterogeneity and plasticity. GSCs exist in a transcriptional gradient between two states: Developmental (Dev) and Injury Response (IR) in which IR-GSCs exhibit more invasive behaviors. While previo...
Molaei, F.
•
MacLeod, G.
•
Haider, S.
•
Tiffany, A.
...•
Angers, S.
biorxiv
Sat Apr 12 2025
Metabolic buffering suppresses phenotype switching in cancer
The impact of the microenvironment on epigenetically plastic cancer cells underpins phenotypic heterogeneity, a major cause of metastatic dissemination and therapy resistance that together represent the primary cause of cancer-related death. Nutrient limitation is a key microenvironmental stress that can cause a phenotypic transition from proliferation to invasion via activation of the integrated ...
Ramirez-Sanchez, A.
•
Jociles-Ortega, M.
•
Garcia-Martinez, J. M.
•
Torrens-Martinez, I.
...•
Chocarro-Calvo, A.